0
Upcoming Allied Market Research
2023
Autoimmune Hepatitis Drug Market

Autoimmune Hepatitis Drug Market

by Drug Class (Oral antivirals, Immune modulators), by Distribution Channel (Hospital pharmacies, Drug stores & retail pharmacies, Online providers) : Global Opportunity Analysis and Industry Forecast, 2022-2032

Report Code: A50576
Pages: NA
May 2023 | 20 Views
Author(s) : Onkar S
Tables: NA
Charts: NA
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 
Autoimmune hepatitis is a chronic liver disease caused by an abnormal immune response against liver cells, leading to inflammation and liver damage. The disease affects primarily women and can occur at any age, but it is more common in middle-aged individuals. The goal of treatment for autoimmune hepatitis is to suppress the immune system and prevent further liver damage. The current standard of care for autoimmune hepatitis includes the use of immunosuppressive medications such as corticosteroids and azathioprine. These drugs are effective in inducing remission in most patients, but they can have significant side effects and may not be effective in all cases. As a result, there is a need for new and improved treatments for autoimmune hepatitis.
Autoimmune hepatitis (AIH) is a chronic liver disease that occurs when the body's immune system attacks liver cells, causing inflammation and damage. AIH can progress to cirrhosis and liver failure if left untreated. The exact cause of AIH is unknown, but it is believed to be triggered by a combination of genetic and environmental factors. AIH is a rare disease, with a prevalence of 10-40 cases per 100,000 individuals in North America and Europe. It is more common in women than men and can occur at any age, although it is most commonly diagnosed in individuals between the ages of 15 and 40. AIH is also more prevalent in certain ethnic groups, including individuals of Northern European and Middle Eastern descent.
Several drugs are currently in development for the treatment of autoimmune hepatitis. One promising drug is B-701, a monoclonal antibody that targets a specific protein on B cells, a type of immune cell that plays a role in autoimmune diseases. B-701 has shown promising results in early clinical trials, with a favorable safety profile and the potential to improve outcomes for patients with autoimmune hepatitis. Another drug in development is EYP001, a small molecule inhibitor of the Janus kinase (JAK) pathway. The JAK pathway is involved in immune cell signaling and has been implicated in autoimmune diseases such as rheumatoid arthritis and ulcerative colitis. EYP001 has shown promising results in preclinical studies and is currently in early-stage clinical trials for the treatment of autoimmune hepatitis.
Furthermore, in recent years, the autoimmune hepatitis (AIH) drug market has seen significant developments in the development of new treatments, including novel immunosuppressive agents and combination therapies. These treatments are increasing the options available to clinicians and improving patient outcomes. One example of a novel immunosuppressive agent is mycophenolate mofetil (MMF). MMF has been shown to be effective in inducing and maintaining remission in AIH patients who do not respond to or cannot tolerate traditional treatment with corticosteroids. It works by inhibiting the proliferation of lymphocytes and reducing the production of antibodies, which are the hallmarks of autoimmune disease.
Another combination therapy is the combination of MMF and corticosteroids. This therapy has been shown to be effective in inducing remission in AIH patients who do not respond to traditional treatment, and it may have fewer side effects than traditional treatment with corticosteroids alone. Overall, these developments in new treatments and combination therapies are improving the options available to clinicians and the outcomes for AIH patients. However, further research is needed to optimize these treatments and identify new targets for therapy in AIH.
 
New product launches to flourish in the market
There have been several new product launches in the AIH drug market in recent years: Imraldi (adalimumab): In October 2018, Samsung Bioepis launched Imraldi, a biosimilar version of Humira (adalimumab), for the treatment of various autoimmune diseases, including AIH; Maviret (glecaprevir/pibrentasvir): In August 2018, AbbVie launched Maviret, a combination therapy for the treatment of chronic hepatitis C, including in patients with AIH; Zeposia (ozanimod): In March 2020, Bristol-Myers Squibb launched Zeposia, a sphingosine 1-phosphate receptor modulator, for the treatment of relapsing forms of multiple sclerosis. While not specifically approved for AIH, it is being studied for its potential use in the disease; Lupkynis (voclosporin): In January 2021, Aurinia Pharmaceuticals launched Lupkynis, an oral calcineurin inhibitor, for the treatment of lupus nephritis. While not specifically approved for AIH, it is being studied for its potential use in the disease.
 
Segment Overview: 
By Drug Class: The autoimmune hepatitis drug market is divided into Oral antivirals and Immune modulators. Oral antivirals may be used as adjunctive therapy in some cases, such as when a patient with AIH also has a viral infection such as hepatitis B or C. In such cases, antivirals can be used to treat the viral infection and help prevent further liver damage. Examples of oral antivirals that may be used in combination with other medications for AIH treatment include: Entecavir (Baraclude), Tenofovir (Viread) and Sofosbuvir (Sovaldi). Moreover, immune modulators are a class of drugs used in the treatment of autoimmune hepatitis (AIH) to suppress the immune system and reduce inflammation in the liver. These drugs work by targeting specific components of the immune system involved in the autoimmune response, such as T-cells and B-cells.
 
By Distribution Channel: The autoimmune hepatitis drug market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Autoimmune hepatitis drugs are typically prescription medications that are used to treat autoimmune hepatitis, a chronic inflammatory liver disease. These drugs are typically available through hospital pharmacies, drug stores and retail pharmacies, and online providers. Hospital pharmacies are typically the primary source of these drugs for patients who are receiving treatment in a hospital setting. Drug stores and retail pharmacies, such as CVS and Walgreens, are also common providers of autoimmune hepatitis drugs for patients who are receiving treatment on an outpatient basis. Patients can obtain their prescriptions from their healthcare providers and then fill them at a local pharmacy.
 
In recent years, online providers have become increasingly popular as a source of prescription medications, including autoimmune hepatitis drugs. Online providers may offer the convenience of home delivery and the ability to order refills online. However, patients should exercise caution when ordering prescription medications online and ensure that they are purchasing from a reputable and licensed provider.
 
By Region: The Asia-Pacific autoimmune hepatitis drug market is one of the fastest-growing markets globally, driven by a combination of factors such as increasing incidence of autoimmune hepatitis, rising awareness about the disease, improving healthcare infrastructure, and growing government initiatives to provide better healthcare facilities. Some of the examples of autoimmune hepatitis drugs that are gaining traction in the region include: Prednisone and Azathioprine, which is widely used as a first-line treatment for autoimmune hepatitis. The drug combination is effective in controlling inflammation and preventing liver damage. In addition, Mycophenolate mofetil is an immunosuppressive drug and is gaining popularity in the region as a second-line treatment option for autoimmune hepatitis. Mycophenolate mofetil is effective in controlling inflammation and reducing the need for high-dose steroid therapy.
 
Furthermore, Tacrolimus drug is another immunosuppressive agent that is used to treat autoimmune hepatitis in the region. Tacrolimus is generally used as a salvage therapy for patients who do not respond to standard treatment. Budesonide is an alternative to prednisone and is effective in reducing inflammation in the liver. It is particularly useful for patients with mild to moderate autoimmune hepatitis. Overall, the Asia-Pacific autoimmune hepatitis drug market is expected to grow rapidly in the coming years, driven by increasing awareness and better treatment options for this chronic inflammatory liver disease.
 
Competitive analysis and profiles of the major players in the autoimmune hepatitis drug market, such as AbbVie Inc., Bristol Myers & Squibb, Cipla Ltd, Gilead Sciences, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Lupin, Merck & Co. Inc., Teva Pharmaceutical Industries Limited and Zydus Wellness Ltd are provided in the report. Major players have adopted product launch and acquisition as key developmental strategies to improve the product portfolio of the autoimmune hepatitis drug market.     

Autoimmune Hepatitis Drug Market Report Highlights

Aspects Details
By Drug Class
  • Oral antivirals
  • Immune modulators
By Distribution Channel
  • Hospital pharmacies
  • Drug stores & retail pharmacies
  • Online providers
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players AbbVie Inc., Bristol Myers & Squibb, Cipla Ltd, Gilead Sciences, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Lupin, Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Zydus Wellness Ltd
 

Loading Table Of Content...


 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now

Purchase Full Report of
Autoimmune Hepatitis Drug Market

Start reading.
This Report and over 19,950+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers